Large Comparative Trials Deserve More Support, FDAer Says
Executive Summary
Thrombolytic agent mortality studies demonstrate the value of large head-to-head trials to detect small outcomes differences between drugs, Center for Drug Evaluation & Research Acting Deputy Director Mark Goldberger said